Update on Routine Immunizations for Children and Adolescents

Gretchen M. Irwin, MD, MBA

American Family Physician. 2025;111(5):419-426.

Author disclosure: No relevant financial affiliations.

This clinical content conforms to AAFP criteria for CME.

Childhood and adolescent immunizations compose a valuable public health tool to prevent infection, morbidity, and mortality. The American Academy of Family Physicians recommends that patients receive all recommended immunizations from their usual source of primary care and does not support nonmedical immunization exemptions. Maintaining high vaccination coverage is crucial for preventing outbreaks of vaccine-preventable diseases. Less than 70% of US children have received the full series of recommended vaccinations at 24 months of age. Using electronic health record reminders and creating standing orders to vaccinate according to protocol at every visit can address practice barriers to vaccination. Whereas most routine childhood immunizations have remained the same for the past 10 years, several considerable changes have occurred. With few exceptions, COVID-19 immunizations are recommended annually for all children to prevent disease and hospitalization and to decrease the risk of post–COVID-19 condition. New pneumococcal vaccine formulations that protect against more serotypes are recommended. Pneumococcal vaccination decreases the risk of meningitis, pneumonia, and possibly acute otitis media in children. Either respiratory syncytial virus immunization for the mother between 32 and 36 weeks of gestation from September to January or the monoclonal antibody nirsevimab for the infant from October to March are now recommended for all mother-infant dyads to prevent severe illness.

GRETCHEN M. IRWIN, MD, MBA, is an associate professor in the Department of Family and Community Medicine at the University of Kansas School of Medicine, Wichita.

Address correspondence to Gretchen M. Irwin, MD, MBA, at girwin2@kumc.edu.

Author disclosure: No relevant financial affiliations.

  1. 1.Carrico J, La EM, Talbird SE, et al. Value of the immunization program for children in the 2017 US birth cohort. Pediatrics. 2022;150(3):e2021056007.
  2. 2.Hill HA, Yankey D, Elam-Evans LD, et al. Decline in vaccination coverage by age 24 months and vaccination inequities among children born in 2020 and 2021—National Immunization Survey-Child, United States, 2021–2023. MMWR Morb Mortal Wkly Rep. 2024;73(38):844-853.
  3. 3.Seither R, Yusuf OB, Dramann D, et al. Coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten – United States, 2022–23 school year. MMWR Morb Mortal Wkly Rep. 2023;72(45):1217-1224.
  4. 4.American Academy of Family Physicians. Immunizations. October 2023. Accessed November 22, 2024. https://www.aafp.org/about/policies/all/immunizations.html
  5. 5.American Academy of Family Physicians. Immunization exemptions. December 2024. Accessed April 1, 2025. https://www.aafp.org/about/policies/all/immunization-exemptions.html
  6. 6.Cooper S, Schmidt BM, Sambala EZ, et al. Factors that influence parents’ and informal caregivers’ views and practices regarding routine childhood vaccination: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2021(10):CD013265.
  7. 7.Paterson P, Meurice F, Stanberry LR, et al. Vaccine hesitancy and healthcare providers. Vaccine. 2016;34(52):6700-6706.
  8. 8.Jacobson Vann JC, Jacobson RM, Coyne-Beasley T, et al. Patient reminder and recall interventions to improve immunization rates. Cochrane Database Syst Rev. 2018(1):CD003941.
  9. 9.Jong KM, Sikora CA, MacDonald SE. Childhood immunization appointment reminders and recalls: strengths, weaknesses and opportunities to increase vaccine coverage. Public Health. 2021;194:170-175.
  10. 10.Bordley WC, Chelminski A, Margolis PA, et al. The effect of audit and feedback on immunization delivery: a systematic review. Am J Prev Med. 2000;18(4):343-350.
  11. 11.Briss PA, Rodewald LE, Hinman AR, et al. Reviews of evidence regarding interventions to improve vaccination coverage in children, adolescents, and adults. The Task Force on Community Preventive Services. Am J Prev Med. 2000;18(1suppl):97-140.
  12. 12.Shay LA, Baldwin AS, Betts AC, et al. Parent-provider communication of HPV vaccine hesitancy. Pediatrics. 2018;141(6):e20172312.
  13. 13.Cataldi JR, Kerns ME, O’Leary ST. Evidence-based strategies to increase vaccination uptake: a review. Curr Opin Pediatr. 2020;32(1):151-159.
  14. 14.MacDonald NE, Harmon S, Dube E, et al. Mandatory infant & childhood immunization: rationales, issues and knowledge gaps. Vaccine. 2018;36(39):5811-5818.
  15. 15.Public Health Law; Center for State, Tribal, Local, and Territorial Support; Centers for Disease Control and Prevention. State school immunization requirements and vaccine exemption laws. February 2022. Accessed November 22, 2024. https://www.cdc.gov/phlp/docs/school-vaccinations.pdf
  16. 16.Centers for Disease Control and Prevention. Child immunization schedule notes. November 21, 2024. Accessed April 1, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html?CDC_AAref_Val=https://www.cdc.gov/vaccines/schedules/hcp/imz/child-schedule-notes.html
  17. 17.US Food and Drug Administration. Vaccines licensed for use in the United States. Accessed May 1, 2024. https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states
  18. 18.Centers for Disease Control and Prevention. Child immunization schedule notes. COVID-19 vaccination. November 21, 2024. Accessed January 14, 2025. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-notes.html#note-covid-19
  19. 19.Beladiya J, Kumar A, Vasava Y, et al. Safety and efficacy of COVID-19 vaccines: a systematic review and meta-analysis of controlled and randomized clinical trials. Rev Med Virol. 2024;34(1):e2507.
  20. 20.Poukka E, Andersson NW, Thiesson EM, et al. COVID-19 vaccine effectiveness among adolescents. Pediatrics. 2024;153(2):e2023062520.
  21. 21.Zambrano LD, Newhams MM, Simeone RM, et al.; Overcoming COVID-19 Investigators. Durability of original monovalent mRNA vaccine effectiveness against COVID-19 Omicron-associated hospitalization in children and adolescents – United States, 2021–2023. MMWR Morb Mortal Wkly Rep. 2024;73(15):330-338.
  22. 22.Flaxman S, Whittaker C, Semenova E, et al. Assessment of COVID-19 as the underlying cause of death among children and young people aged 0 to 19 years in the US. JAMA Netw Open. 2023;6(1):e2253590.
  23. 23.Razzaghi H, Forrest CB, Hirabayashi K, et al.; RECOVER Consortium. Vaccine effectiveness against long COVID in children. Pediatrics. 2024;153(4):e2023064446.
  24. 24.Sherman AC, Tuan J, Cantos VD, et al. COVID-19 vaccine efficacy in participants with weakened immune systems from 4 randomized controlled trials. Clin Infect Dis. 2024;79(2):364-374.
  25. 25.Centers for Disease Control and Prevention. Vaccination trends. March 21, 2025. Accessed April 1, 2025. https://www.cdc.gov/respiratory-viruses/data/vaccination-trends.html?CDC_AAref_Val=https://www.cdc.gov/respiratory-viruses/data-research/dashboard/vaccination-trends-children.html
  26. 26.Aldridge SJ, Agrawal U, Murphy S, et al. Uptake of COVID-19 vaccinations amongst 3,433,483 children and young people: meta-analysis of UK prospective cohorts. Nat Commun. 2024;15(1):2363.
  27. 27.Watanabe A, Kani R, Iwagami M, et al. Assessment of efficacy and safety of mRNA COVID-19 vaccines in children aged 5 to 11 years: a systematic review and meta-analysis. JAMA Pediatr. 2023;177(4):384-394.
  28. 28.Cortese MM, Taylor AW, Akinbami LJ, et al. Surveillance for multisystem inflammatory syndrome in US children aged 5–11 years who received Pfizer-BioNTech COVID-19 vaccine, November 2021 through March 2022. J Infect Dis. 2023;228(2):143-148.
  29. 29.Costa C, Moniati F. The epidemiology of COVID-19 vaccine-induced myocarditis. Adv Med. 2024;2024:4470326.
  30. 30.US Food and Drug Administration. FDA approves required updated warning in labeling of mRNA COVID-19 vaccines regarding myocarditis and pericarditis following vaccination. June 25, 2025. Accessed August 25, 2025. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-approves-required-updated-warning-labeling-mrna-covid-19-vaccines-regarding-myocarditis-and [updated]
  31. 31.Husby A, Gulseth HL, Hovi P, et al. Clinical outcomes of myocarditis after SARS-CoV-2 mRNA vaccination in four Nordic countries: population based cohort study. BMJ Med. 2023;2(1):e000373.
  32. 32.Uraguchi K, Matsumoto N, Mitsuhashi T, et al. Pediatric otitis media in Japan: a nationwide longitudinal study of the pre- and post-pneumococcal conjugate vaccine eras born in 2001 and 2010. Vaccine. 2024;42(19):4081-4087.
  33. 33.Hsu HE, Shutt KA, Moore MR, et al. Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med. 2009;360(3):244-256.
  34. 34.Feikin DR, Karron RA, Saha SK, et al. The full value of immunisation against respiratory syncytial virus for infants younger than 1 year: effects beyond prevention of acute respiratory illness. Lancet Infect Dis. 2024;24(5):e318-e327.
  35. 35.Fleming-Dutra KE, Jones JM, Roper LE, et al. Use of the Pfizer respiratory syncytial virus vaccine during pregnancy for the prevention of respiratory syncytial virus-associated lower respiratory tract disease in infants: recommendations of the Advisory Committee on Immunization Practices – United States, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(41):1115-1122.
  36. 36.Kampmann B, Madhi SA, Munjal I, et al.; MATISSE Study Group. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants. N Engl J Med. 2023;388(16):1451-1464.
  37. 37.Venkatesan P. Nirsevimab: a promising therapy for RSV. Lancet Microbe. 2022;3(5):e335.
  38. 38.Drysdale SB, Cathie K, Flamein F. Nirsevimab for prevention of hospitalizations due to RSV in infants. N Engl J Med. 2023;389(26):2425-2435.
  39. 39.Ackerman LK, Serrano JL. Update on routine childhood and adolescent immunizations. Am Fam Physician. 2015;92(6):460-468.
  40. 40.Ackerman LK. Update on immunizations in children and adolescents. Am Fam Physician. 2008;77(11):1561-1568.
  41. 41.Zuin M, Rigatelli G, Bilato C, et al. One-year risk of myocarditis after COVID-19 infection: a systematic review and meta-analysis. Can J Cardiol. 2023;39(6):839-844. [updated]

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.